Answers are grounded in this paper and cite their sources.
Goldberg et al. (1) report a randomized comparison of the effects of two thiazolidinediones (TZDs), pioglitazone (Actos) and rosiglitazone (Avandia), on lipid and lipoprotein levels in individuals with diabetes treated with diet and/or oral monotherapy. Many changes in these lipids and lipoproteins seemed to be in favor of pioglitazone. Two important pieces of information were not included in the published study. …
No takes yet. Share an insight, caveat, or question.
John D. Brunzell (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: